The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Left ventricular ejection fraction (EF) remains the major parameter for diagnosis,
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …

Background Experimental and clinical evidence supports the role of inflammation in
atherosclerosis and its complications. Colchicine is an orally administered, potent …

Background Patients with elevated triglyceride levels are at increased risk for ischemic
events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers …

Heart failure is the most common cardiovascular reason for hospital admission for people
older than 60 years of age. Few areas in medicine have progressed as remarkably as heart …

Background Intravenous ferric carboxymaltose has been shown to improve symptoms and
quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate …

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to
reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …